GlassScriptPhysician profile
Daniel A Adelberg
NPI 1225000557
$8,554.42
in general payments reported to CMS, 2019-2025
29 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 81% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $19.01 · 2021: $476 · 2022: $1,193 · 2023: $2,344 · 2024: $2,576 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,068 · Consulting Fee: $378 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,068.43 |
| Consulting Fee | $378.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,982.87 | 2022-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $1,153.90 | 2021-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $994.93 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $985.44 | 2023-2025 | Eylea Hd, Eylea |
| Glaukos Corporation | $384.89 | 2022-2025 | Idosetr |
| Astellas Pharma US INC | $321.73 | 2023-2025 | Izervay |
| Alcon Vision LLC | $270.62 | 2019-2025 | Tryptyr |
| Bausch & Lomb Americas INC. | $213.61 | 2022-2025 | Xipere, Visudyne, Retisert |
| Novartis Pharmaceuticals Corporation | $204.76 | 2019 | |
| Abbvie INC. | $196.32 | 2024-2025 | |
| Horizon Therapeutics Plc | $164.96 | 2019-2022 | |
| Allergan, INC. | $128.17 | 2021 | |
| Biogen, INC. | $77.37 | 2022-2023 | |
| Eyepoint US, INC. | $76.05 | 2019-2022 | |
| Harrow Eye, LLC | $55.10 | 2025 | Iheezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $51.49 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Oyster Point Pharma, INC. | $35.41 | 2023-2024 | Tyrvaya |
| Mallinckrodt Enterprises LLC | $29.27 | 2019 | |
| Dompe US, INC. | $23.74 | 2025 | Oxervate |
| Coopervision INC. | $22.76 | 2023 | Myday Contact Lens |
| New World Medical,INC. | $20.30 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Ani Pharmaceuticals, INC. | $19.45 | 2025 | Yutiq |
| Spark Therapeutics, INC. | $19.44 | 2021 | |
| Aerie Pharmaceuticals, INC. | $18.88 | 2019 | |
| Genentech, INC. | $18.71 | 2024 | Vabysmo, Susvimo |
| Amgen INC. | $16.54 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.57 | 2019 | |
| Shire North American Group INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Adelberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.